Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF)

You'll hear about Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF).

Kalydeco (ivacaftor) is the first drug that treats the underlying genetic mutation that causes CF...not just its symptoms.

Unfortunately, it'll only help the 4% of CF patients who have a rare genetic mutation. But in the future, you'll see drugs that target more common mutations that cause CF.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote